In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ipsen and Roche to develop diabetes therapeutic; terminated

Executive Summary

Following closely on their first co-development and co-promotion collaboration (signed in December 2002 for anticancer agents), Ipsen and Roche are again collaborating to develop Ipsen's BIM51077 glucagon-like peptide-1 (GLP-1) analog, which is now in Phase I clinical trials to treat Type II diabetes.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies